Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho
Diseases (2020) Vol. 8, Iss. 2, pp. 14-14
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Keming Huang, Xianling Luo, Bin Liao, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 46
Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline
Antonio Lardaro, L. Quarta, Stefania Pagnotta, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1750-1750
Open Access | Times Cited: 19
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4502-4515
Open Access | Times Cited: 99
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 81
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 40
SGLT2 Inhibitors as Potential Anticancer Agents
Debasish Basak, David Gamez, Subrata Deb
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1867-1867
Open Access | Times Cited: 40
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 322-322
Open Access | Times Cited: 25
Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI
Barkın Kültürsay, Cemalettin Yılmaz, Barış Güven, et al.
Kardiologia Polska (2024) Vol. 82, Iss. 1, pp. 29-36
Open Access | Times Cited: 12
Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients
Pojsakorn Danpanichkul, Worapaka Manosroi, Tharadon Nilsirisuk, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 10
SGLT2 Inhibitors in Kidney Diseases—A Narrative Review
Agata Gajewska, Jakub Wasiak, Natalia Sapeda, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4959-4959
Open Access | Times Cited: 10
Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling
Jingjing Zhang, X. Ye, Xuesong Liu, et al.
World Journal of Cardiology (2025) Vol. 17, Iss. 1
Closed Access | Times Cited: 1
Cardiovascular outcomes with SGLT-2 inhibitors in individuals with diabetes and co-existing atrial fibrillation: A systematic review and meta-analysis
Muhammad Zain Ameer, Muhammad Aemaz Ur Rehman, Zunaira Amjad, et al.
International Journal of Cardiology (2025), pp. 133083-133083
Closed Access | Times Cited: 1
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
V. A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines (2022) Vol. 10, Iss. 2, pp. 274-274
Open Access | Times Cited: 37
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Rosanna Maccari, Rosaria Ottanà
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10848-10881
Open Access | Times Cited: 31
Weight-centric treatment of type 2 diabetes mellitus
Wissam Ghusn, Maria D. Hurtado, Andrés Acosta
Obesity Pillars (2022) Vol. 4, pp. 100045-100045
Open Access | Times Cited: 29
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
Sunetra Mondal, Subhodip Pramanik, Vibhu Ranjan Khare, et al.
World Journal of Cardiology (2024) Vol. 16, Iss. 5, pp. 240-259
Open Access | Times Cited: 6
Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications
Abhishek Satheesan, Janardanan Kumar, K.V. Leela, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 2753-2779
Closed Access | Times Cited: 6
New Insights into the Use of Empagliflozin—A Comprehensive Review
Joanna Forycka, Joanna Hajdys, Julia Krzemińska, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3294-3294
Open Access | Times Cited: 25
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review
Liana Iordan, Laura Gaiță, Romulus Timar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7057-7057
Open Access | Times Cited: 5
The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data
Jie Zheng, Jieli Lu, Jiying Qi, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 8, pp. 101688-101688
Open Access | Times Cited: 5
Transcriptional profiling of transport mechanisms and regulatory pathways in rat choroid plexus
Søren Norge Andreassen, Trine L. Toft‐Bertelsen, Jonathan H. Wardman, et al.
Fluids and Barriers of the CNS (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 22
Effect of SGLT2-Inhibitors on Polygraphic Parameters in Elderly Patients Affected by Heart Failure, Type 2 Diabetes Mellitus, and Sleep Apnea
Giuseppe Armentaro, Corrado Pelaia, Valentino Condoleo, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 937-937
Open Access | Times Cited: 4
Cardiovascular outcomes of SGLT-2 inhibitors’ subtypes in type 2 diabetes; an updated systematic review and meta-analysis of randomized controlled trials
Pouya Ebrahimi, Hamidreza Soleimani, Mehrdad Mahalleh, et al.
Journal of Diabetes & Metabolic Disorders (2025) Vol. 24, Iss. 1
Closed Access
Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database
Yuwei Liu, Xu Zhao, Xinrui Wang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top